Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | TOP1 | P11387 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 3/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25934670 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL21901457 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL27291420 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL27291402 | 0.95 | LMNA (0.50) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL18644645 | 0.95 | LMNA (0.50) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL32670368 | 0.93 | L3MBTL1 (0.50) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL32670311 | 0.91 | LMNA (0.48) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL14199854 | 0.91 | LMNA (0.48) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL26073710 | 0.88 | LMNA (0.50) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL13026578 | 0.88 | LMNA (0.50) | LMNAL3MBTL1TDP1TOP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | LMNA 676/4885L3MBTL1 1722/4885TDP1 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.